TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01743586

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Chest physiotherapy education intervention
Description: breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
Study: NCT03661268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid chanllenge
Description: A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
Study: NCT03233100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: fecal microbiota transplantation
Study: NCT04417530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Microinjector
Description: Suprachoroidal Injection Device
Study: NCT02274324

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: different diets
Description: 3 different diets: A\\B\\C

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: different diets
Description: 3 different diets: A\\B\\C
Study: NCT04417530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Microinjector
Description: Suprachoroidal Injection Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Microinjector
Description: Suprachoroidal Injection Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Laser
Description: Laser Administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Laser
Description: Laser Administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Laser
Description: Laser Administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Laser
Description: Laser Administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Laser
Description: Laser Administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Laser
Description: Laser Administration
Study: NCT01929694

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berocca Boost

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00356187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study: NCT00815633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: 15mg intramuscular injection weekly for 12 weeks
Study: NCT00455702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: 50mg dose d-cycloserine v placebo
Study: NCT03948581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study: NCT04033575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Total SF
Description: 1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Colgate Cavity Protection toothpaste
Description: 0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
Study: NCT04448938

Intervention type: OTHER
Intervention: MRI
Description: The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO.

Intervention type: OTHER
Intervention: MRI
Description: The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO.

Intervention type: OTHER
Intervention: visual acuity
Description: Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
Study: NCT02891694

Intervention type: OTHER
Intervention: in vitro immuno-histo-chemical analysis of corneal epithelium

Intervention type: OTHER
Intervention: in vitro immuno-histo-chemical analysis of corneal epithelium
Study: NCT01516164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy
Description: After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
Study: NCT05797259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danosumab
Description: 60 mg subcutaneous Danosumab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo comparator arm
Study: NCT04633733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237 tablet
Description: HL237 400mg will be administered orally twice a day.
Study: NCT04304534

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BAY2433334 matching placebo
Description: Tablet, taken orally once a day.
Study: NCT00897637

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03315390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy-oriented intervention
Description: Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
Study: NCT03315390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: improved treatment as usual (iTAU)
Description: improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
Study: NCT02931435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block with Radiofrequency Ablation
Description: Ablation of the genicular nerves of the knee by radiofrequency

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Nerve Block with Sham Radiofrequency Ablation
Description: Genicular radiofrequency of the knee without neurotomy
Study: NCT00286741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Group Management Visits
Description: Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
Study: NCT00455702

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: d-cycloserine
Description: 50mg dose d-cycloserine v placebo
Study: NCT01771497

Intervention type: DEVICE
Intervention: Koning Breast CT
Description: Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
Study: NCT01326169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: Telephone-delivered counseling
Study: NCT00939848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20mg od (continuous dosing) until evidence of disease progression has been confirmed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib
Description: cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
Study: NCT03154944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostomy device 1
Description: This device consists of a known adhesive and a new top film

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostomy device 2
Description: This device consists of a new adhesive and a known top film

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostomy device 3
Description: This device consists of a known adhesive and a new top film
Study: NCT03252106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contour augmentation with implant placement
Description: Contour augmentation with implant placement
Study: NCT04042519

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.
Description: This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.
Description: This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.
Description: This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
Study: NCT01326169

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: No intervention
Study: NCT01295112

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Active bevacizumab and Sham dexamethasone
Description: Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bevacizumab and Active dexamethasone
Description: Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
Study: NCT04547738

Intervention type: DRUG
Intervention: TB treatment according to national guidelines
Description: National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis

Intervention type: DRUG
Intervention: TB treatment according to national guidelines
Description: National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
Study: NCT01244542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: unpleasant stimuli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unpleasant stimuli
Study: NCT02610556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 2
Description: Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 1
Description: Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Intensity-modulated radiotherapy
Study: NCT03381196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC Treatment
Description: Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC Treatment
Description: Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
Study: NCT01544439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stabilizing appliance
Description: The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-occluding splint, counseling
Description: The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
Study: NCT02898701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Practice of a Standing Serial Reaction Time Task
Description: Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Practice of a Standing Serial Reaction Time Task
Description: Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Practice of a Standing Serial Reaction Time Task
Description: Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
Study: NCT00602537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: 75 to 375 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: 300 to 2400 mg
Study: NCT00813345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light therapy (1500 lux)
Description: light therapy (1500 lux) for 90 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard light (100 LUX)
Description: standard light (100 LUX) for 90 minutes
Study: NCT00388037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01899196

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling,
Study: NCT00533806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
Study: NCT01806610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804
Description: Single dose BPS804 administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo administration.
Study: NCT05778240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Description: Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions.~1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace?~2. What kind of transportation do you plan to take to come to the hospital at your appointment day?~3. At what time do you plan to leave home or work to come to the hospital?

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants were given the vaccination appointment card.
Study: NCT04633733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus capsule
Description: tacrolimus 5mg will be administered orally once a day.
Study: NCT01554683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low/High/Placebo Dose Keppra (Levetiracetam)
Description: Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low/High/Placebo Dose Keppra (Levetiracetam)
Description: Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low/High/Placebo Dose Keppra (Levetiracetam)
Description: Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
Study: NCT01191411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mailed invitations for FIT test kits
Description: Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mailed invitations for a colonoscopy
Description: These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit Based Care
Description: Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.